This study provides evidence for the importance of p21 CDKN1A for the repair of replication-mediated DNA double-strand breaks (DSBs) induced by topoisomerase I. We report that defects of p21 CDKN1A and p53 enhance camptothecin-induced histone H2AX phosphorylation (cH2AX), a marker for DNA DSBs. In human colon carcinoma HCT116 cells with wild-type (wt) p53, cH2AX reverses after camptothecin removal. By contrast, cH2AX increases after camptothecin removal in HCT116 cells deficient for p53 (p53À/À) or p21 CDKN1A (p21À/À) as the cells reach the late-S and G2 phases. Since p21À/À cells exhibit similar S-phase arrest as wt cells in response to camptothecin and aphidicolin does not abrogate the enhanced cH2AX formation in p21À/À cells, we conclude that enhanced cH2AX formation in p21À/À cells is not due to re-replication. The cell cycle checkpoint abrogator and Chk1/Chk2 inhibitor 7-hydroxystaurosporine (UCN-01) also increases camptothecin-induced cH2AX formation and inhibits camptothecin-induced p21 CDKN1A upregulation in HCT116 wt cells. TUNEL (terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling) assays demonstrate that cH2AX formation in late S and G2 cells following CPT treatment corresponds to DNA breaks. However, these breaks are not related to apoptotic DNA fragmentation. We propose that p21
Introduction
After DNA damage, cell cycle progression is slowed down or arrested by cell cycle checkpoints, presumably in order to provide time to repair damaged DNA and prevent accumulation of deleterious mutations (Weinert, 1998; Melo and Toczyski, 2002) . Cell cycle checkpoints exist at the G1/S and G2/M transitions, and during the S phase of the cell cycle (S-phase checkpoint) (Foiani et al., 1998; O'Connell et al., 2000) . The specific checkpoint pathways activated depend on the nature, degree and timing of DNA damage, and on the genetic and epigenetic program of the cells. Reversible arrest by checkpoints provides an adaptive response to DNA damage that enables DNA repair. Checkpoint activation can also lead to apoptosis (for instance in the case of p53 activation), and irreversible cell cycle arrest to prevent propagation of cells with genetic abnormalities.
The p53/p21 CDKN1A checkpoint pathway is inactivated in more than 50% of human cancers. In response to DNA damage, the p53/p21 CDKN1A pathway arrests cells at the G1/S and G2/M checkpoints (Kachnic et al., 1999; Taylor and Stark, 2001; Gudkov and Komarova, 2003; Kohn and Pommier, 2005) . At the molecular level, p21
CDKN1A inhibits the activity of cyclin/cdk's and regulates the activity of PCNA, thereby blocking cell cycle progression and DNA replication. The p53/ p21 CDKN1A pathway has also been implicated in DNA repair (Fujimori et al., 1996; Taylor and Stark, 2001) and apoptosis (Han et al., 2002; Zhivotovsky and Kroemer, 2004) .
Camptothecin is a specific topoisomerase I inhibitor (Liu et al., 2000; Pommier and Cherfils, 2005) whose derivatives are among the most effective novel anticancer drugs (http://www.discover.nci.nih.gov/pommier/ pommier.htm). Camptothecins convert topoisomerase I, an essential enzyme in higher eukaryote, to a cellular poison when replication forks collide with camptothecin-trapped topoisomerase I cleavage complexes (Pommier et al., 2003 (Pommier et al., , 2006 . The resulting lesions are replication-mediated, DNA double-strand breaks (DSBs) (see Figure 8 , inset) (Strumberg et al., 2000; Furuta et al., 2003) , which are the primary mechanism for killing tumor cells by camptothecins. As topoisomerase I is present both in normal tissues and tumors, the anticancer selectivity of camptothecins is likely because of tumor-specific defects in downstream pathways including cell cycle checkpoints and DNA repair (Pommier et al., 2003 (Pommier et al., 2006 (http://www.discover. nci.nih.gov/pommier/pommier.htm).
A common step following replication-mediated DSBs is the activation of sensor kinases belonging to the family of phosphatidylinositol-3-OH kinase-related kinases (PIKKs) (Abraham, 2004) . Three PIKKs are activated by topoisomerase I-induced replicationmediated DSBs: ATR (ataxia teleangiectasia mutated and Rad3 related), ATM (ataxia teleangiectasia mutated) and DNA-dependent protein kinase (DNA-PK) (Goldwasser et al., 1996; Shao et al., 1999; Wan et al., 1999; Ward and Chen, 2001; Wu et al., 2002; Rao et al., 2005) . Consistent with the importance of these pathways for cellular response to camptothecins, cells deficient for ATM, ATR or DNA-PK are hypersensitive to camptothecins (see Table 1 in Pommier et al. (2003) and Table 2 in Pommier et al. (2006) ).
ATM, ATR and DNA-PK activate the DSB signaling pathways by phosphorylating a range of nuclear proteins, including histone H2AX and p53 (Hoeijmakers, 2001; Shiloh, 2003; Motoyama and Naka, 2004; Sancar et al., 2004) . Phosphorylation of histone H2AX on serine 139 generates gH2AX, a sensitive and early marker for DSBs (Rogakou et al., 1998; Redon et al., 2002) . We recently demonstrated that gH2AX is also induced by replication-mediated DSBs (RepDSBs), induced by camptothecin (Furuta et al., 2003) . ATM and ATR phosphorylate p53 directly on serine 15 (Banin et al., 1998; Canman et al., 1998) and indirectly on serine 20 by phosphorylation/activation of Chk2 (Chehab et al., 1999; Caspari, 2000; Hirao et al., 2000; Melchionna et al., 2000) (for a review, see and Chk1 (Shieh et al., 2000) , both of which directly phosphorylate serine 20 of p53. These phosphorylations stabilize p53 and activate its transcriptional activity, leading to increased expression of p21 CDKN1A (Taylor and Stark, 2001; Kohn and Pommier, 2005) . The importance of this pathway is exemplified by the fact that cells deficient for p53 or p21 CDKN1A are hypersensitive to camptothecin (Han et al., 2002) , suggesting that p53 and p21 CDKN1A play key roles for the repair of the camptothecin-induced DSBs, and that p53/p21 CDKN1A deficiencies may contribute to tumor response to camptothecin.
In keeping with this view, we have observed a striking p53-and p21
CDKN1A
-dependent divergence of cellular response among isogenic derivatives of the human colorectal cancer cell line HCT116 treated with the topoisomerase I inhibitor SN38, the active metabolite of irinotecan, a camptothecin derivative effective in treatment of human colorectal cancer. After an initial late S/G2 growth arrest lasting 48 h, HCT116 lacking p53 or p21 CDKN1A undergo apoptosis, whereas wild type (wt) HCT116 or Bax null HCT116, both of which express wt p53 and p21 CDKN1A , remain viable in a prolonged senescence-like growth arrest (Hayward et al., 2003) .
Similar results have recently been reported independently (Tse and Schwartz, 2004) . We investigate the mechanism of this divergent response in camptothecintreated cells in the current paper.
The Chk1/Chk2/p21 CDKN1A checkpoint pathways can be inhibited by 7-hydroxystaurosporine (UCN-01), an indolocarbazole derivative presently in clinical trials (Dancey and Sausville, 2003; Senderowicz, 2003; . UCN-01 inhibits Chk1 (Graves et al., 2000; Kohn et al., 2002) , Chk2 (Yu et al., 2002) and PDK1 (Sato et al., 2002) kinases, as well as p21 CDKN1A expression in response to ionizing radition (IR) (Yu et al., 2002) . Combination of camptothecin followed by UCN-01 enhances the cytotoxicity of camptothecin in a supra-additive manner and abrogates camptothecin-induced S-phase arrest (Shao et al., 1997a; Yu et al., 2002) . UCN-01 also sensitizes preferentially cells deficient for p53 (Fan et al., 1995; Shao et al., 1997a; Tse and Schwartz, 2004; ; Levesque et al., 2005) .
In the present study, we investigated the roles of p53 and p21
CDKN1A on the repair of topoisomerase I-induced replication-mediated DSBs using gH2AX (Furuta et al., 2003) . We compared human colon carcinoma HCT116 cells treated with camptothecin in the absence and in the presence of UCN-01, and their isogenic derivatives in which either p53 or p21 CDKN1A had been knocked out (Waldman et al., 1996; Bunz et al., 1998) . Our results imply an important role for p21 CDKN1A in the processing and repair of replication-mediated DSBs, and further expand the rationale for using camptothecins in cells with functional defects in the p21 CDKN1A pathway, and for combining camptothecins and cell cycle checkpoint inhibitors, such as UCN-01, in cancer chemotherapy.
Results
Enhanced gH2AX formation after camptothecin removal in p53À/À (deficient for p53) or p21À/À (deficient for p21 CDKN1A ) HCT116 cells We previously reported that camptothecin-induced, replication-mediated DSB can be detected as gH2AX foci (Furuta et al., 2003) . In the present study, we followed the reversal of camptothecin-induced gH2AX foci in HCT116 cells containing wt p53 and wt p21 CDKN1A (HCT116 wt), and in their isogenic derivatives, HCT116 p53À/À or HCT116 p21À/À cell lines, in which the p53 and p21
CDKN1A genes are knocked out, respectively (Waldman et al., 1996; Bunz et al., 1998) . Cells were treated with 1 mM camptothecin for 3 h, and gH2AX foci were examined 3 and 6 h following camptothecin removal. gH2AX foci reversed in HCT116 wt cells ( Figure 1A : panels c and d). In HCT116 p53 À/À and p21À/À cells, gH2AX foci also formed in response to camptothecin ( Figure 1A : panels f and j). However, the gH2AX signal intensity of those cells increased after camptothecin removal ( Figure 1A : panels g, h, k and l). The p21À/À cells in particular, displayed intense staining for gH2AX antibody (see Figure 1A : panels k and l). Time-course changes and statistical comparisons p21 , and cH2AX induced by camptothecin T Furuta et al for gH2AX foci in wt, p53À/À and p21À/À cells treated with camptothecin are summarized in Figure 1B . Western blot analyses ( Figure 1C ) also showed increased gH2AX in the p21À/À and p53À/À cells, whereas gH2AX decreased in the HCT116 wt cells after drug removal. Together, the microscopy and Western blotting experiments indicate that the p53/p21 CDKN1A pathway is involved in the reversal of gH2AX induced by topoisomerase I-mediated DNA damage.
The cell cycle checkpoint abrogator UCN-01 blocks p21 CDKN1A upregulation and induces gH2AX formation following camptothecin treatment p21 CDKN1A has been shown to be progressively induced after camptothecin removal (Liu and Zhang, 1998; Liu et al., 2000) . We previously reported that UCN-01 inhibits the upregulation of p21 CDKN1A induced by IR (Yu et al., 2002) . Here, we determined the effect of UCN-01 on the upregulation of p21 CDKN1A induced by camptothecin in HCT116 wt cells. Figure 2A is a scheme of the treatment schedule used. HCT116 wt cells were exposed to 1 mM of camptothecin for 3 h. After camptothecin removal, the cells were either treated with 0.1 mM of UCN-01 or left untreated. Figure 2B shows that, as expected (Nelson and Kastan, 1994) , p21 CDKN1A was progressively induced after 3 and 6 h following camptothecin removal. However, this p21 CDKN1A upregulation was reduced by UCN-01 ( Figure 2B ), indicating that UCN-01 inhibits p21 CDKN1A upregulation in response to topoisomerase I-mediated DNA damage (Nelson and Kastan, 1994) .
Next, we examined the effect of UCN-01 on the reversal of gH2AX after removal of camptothecin in HCT116 wt cells. Addition of UCN-01 after the removal of camptothecin increased the intensity of gH2AX foci ( Figure 2C : panels f and g). Noticeably, UCN-01 alone did not induce gH2AX after 6 h exposure ( Figure 2C : panel e). The effect of UCN-01 on the camptothecininduced gH2AX foci are summarized in Figure 2D . Western blot analyses ( Figure 2E ) confirmed the timedependent increase of gH2AX in UCN-01-treated cells. These results demonstrate that UCN-01 blocks p21 CDKN1A upregulation and increases gH2AX after camptothecin treatment. Thus, HCT116 wt cells treated with UCN-01 were comparable in behavior to the HCT116 p21À/À cells. gH2AX accumulation is maximal at the G2 phases of the cell cycle in p21À/À HCT116 cells and in HCT116 wt cells treated with UCN-01 As only a fraction of the p21À/À or UCN-01-treated HCT116 wt cells showed enhanced gH2AX (see Figure 1A : panels k and l, and Figure 2C : panels f and g), we used the Laser Scanning Cytometry (LSC) technique to determine the relationship between cell cycle phase and generation of gH2AX. Consistent with our recent study (Furuta et al., 2003) , camptothecin induced gH2AX in S-phase HCT116 wt cells (Figure 3 : panel e). Similarly, we found preferential formation of Figure 1 Persistent elevation of gH2AX in HCT116 defective for p21 CDKN1A (p21À/À) or p53 (p53À/À) following camptothecin treatment. (A) Kinetics of gH2AX foci induced by camptothecin and after removal of camptothecin in HCT116 wt (WT) (panels a-d), p53 À/À (panels e-h) and p21 À/À cells (panels i-l). Cells were fixed before treatment (Control), at the end of the 3 h camptothecin treatment (1 mM) (no reversal ¼ R0), and following camptothecin removal after 3 h (R3) and 6 h (R6). Cells were stained with antigH2AX antibody (green) and propidium iodide (red). No gH2AX foci were observed before treatment (a, e, i). In WT cells, camptothecin-induced gH2AX foci (R0) (b) decreased with time 3 (c) and 6 (d) hours after camptothecin removal. By contrast, gH2AX foci increased at 3 (g, k) and 6 h (h, l) after camptothecin removal in p53 À/À, and to a greater extent in p21À/À cells. DNA DSBs in p21À/À HCT116 and HCT116 wt cells treated with UCN-01 following topoisomerase I poisoning by camptothecin As gH2AX is a specific marker for DNA DSBs (Redon et al., 2002; Brown and Baltimore, 2003) , we tested whether DNA breaks could be detected in p21À/À or HCT116 wt cells treated with UCN-01. The TUNEL (terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling) assay was used to visualize DNA breaks ( Figure 4 ). This assay requires the presence of free 3 0 -OH DNA ends for nucleotide incorporation by terminal transferase and fluorescence detection (Tornusciolo et al., 1995) . As camptothecin traps topoisomerase I cleavage complexes with the enzyme covalently linked to the 3 0 end of single-strand nicks, TUNEL-labeling can only be observed after topoisomerase I cleavage complexes have been converted to DSB, or after release of the blocking topoisomerase I at the 3 0 -DNA end of the cleavage complex (Pommier et al., 2003 (Pommier et al., , 2006 . Consistently, TUNEL labeling was not detectable in HCT116 wt cells treated with 1 mM of camptothecin for 3 h ( Figure 4A Western blot analysis for p21 induction by camptothecin (CPT) 1 mM in the absence and presence of UCN-01 0.1 mM. Treatments are indicated above lanes. No p21 was detected before (CL) and at the end of (R0) the camptothecin treatment. p21 was detectable 3 h after camptothecin removal (R3). At 6 h after camptothecin removal (R6), p21 was further increased. UCN-01 inhibited the p21 elevation at the 6 h and to a lesser extent at the 3 h time points. ( þ ): Treated with 0.1 mM of UCN-01 after removal of camptothecin. (À): Incubated in the medium alone after removal of camptothecin. (C) UCN-01 increases gH2AX foci after removal of camptothecin. As shown in Figure 1A , camptothecininduced gH2AX foci after 3 h treatment (R0) (b) decreased by 3 h (c) and 6 h (d) after camptothecin removal. By contrast, when cells were treated with UCN-01 after removal of camptothecin, the intensity of gH2AX foci increased at 3 (f) and 6 (g) hours after removal of camptothecin. Treatment with 0.1 mM of UCN-01 alone for 6 h did not induce gH2AX foci (e). (D) Quantitation of gH2AX foci in HCT116 wt cells treated with camptothecin (CPT) alone, CPT -UCN-01 and UCN-01 alone. Data are expressed as mean7s.e. The statistical significance was assessed by the two-way analysis of variance (ANOVA) followed by the Scheffe's multiple comparison test. Differences in gH2AX intensity between the treated and control cells are omitted. *Po0.05, ** Po0.005. (E) Western blot analysis showing increased gH2AX in UCN-01-treated cells. Treatments are indicated above lanes. No gH2AX was observed in the untreated control cells (CL). When cells were treated with UCN-01 after removal of camptothecin, gH2AX increased with time after removal of camptothecin, although UCN-01 alone did not induce gH2AX. Abbreviations: CL ¼ control untreated cells; R0 ¼ at the end of the treatment with 1 mM of camptothecin for 3 h; R3 ¼ 3 h after removal of camptothecin; R6 ¼ 6 h after removal of camptothecin.
UCN-01, p21, and cH2AX induced by camptothecin T Furuta et al As TUNEL is commonly used to detect apoptotic DSB, we examined Annexin V staining under conditions where cells were TUNEL positive. Figure 4B shows that less than 1% of the cells were positive for Annexin V under the conditions described in Figure 4A irrespective of p21 status, UCN-01 or camptothecin treatment. As gH2AX intensity can also increase in preapoptotic cells (Rogakou et al., 2000; Huang et al., 2004) , we examined chromatin condensations in cells treated with camptothecin. As shown in Figure 4C , no chromatin condensation was observed in the cells with dense staining for gH2AX at 6 h after camptothecin treatment. Nuclear appearances of such cells were the same as those of cells without gH2AX staining. TUNEL staining occurred well before the onset of caspase activation (not shown). Together, the Annexin V, nuclear morphology and caspase experiments indicate that gH2AX observed in p21À/À or UCN-01-treated cells is not related to preapoptotic chromatin condensation.
S-phase checkpoint in p21À/À cells, and in HCT116 wt cells treated with UCN-01 Next, we tested whether gH2AX formation after camptothecin removal in HCT116 p21À/À cells, and in HCT116 wt cells co-treated with UCN-01, was due to a failure in the S-phase checkpoint in response to topoisomerase I-mediated DNA damage. Cells were treated with nocodazole immediately after removal of camptothecin to examine their progression through the first S phase following camptothecin treatment ( Figure 5A ). As previously reported (Shao et al., Figure 3 Selective enhancement of gH2AX by p21 CDKN1A (p21) deficiency and UCN-01 in the late S and G2/M phases of the cell cycle. Treatment protocol is shown in Figure 2A . Analyses were performed by laser scanning microscopy (LSC ). The X-axis indicates the DNA content measured by propidium iodide and the Y-axis the gH2AX signal intensity for each cell. (a and b) CL corresponds to the untreated controls. (c) R0 corresponds to cells examined at the end of the treatment with camptothecin (CPT) 1 mM for 3 h, and R6 to cells examined 6 h after camptothecin removal. gH2AX is maximum in replicating (S phase) HCT116 wt and p21À/À cells (d and e). After camptothecin removal, gH2AX decreases in HCT 116 wt cells (g), whereas gH2AX increases in p21 À/À cells (f) and in HCT116 wt cells incubated with UCN-01 after removal of CPT (h). In both cases, gH2AX intensity is directly correlated with cellular DNA content, and is greatest in late-S and G2/M phase cells. UCN-01 alone (0.1 mM for 6 h) does not induce gH2AX in HCT116 wt cells (c). Abbreviations; CL ¼ control untreated cells; R0 ¼ at the end of the treatment with 1 mM of camptothecin for 3 h; R3 ¼ 3 h after removal of camptothecin; R6 ¼ 6 h after removal of camptothecin. To examine further the difference between p21 CDKN1A deficiency and UCN-01 treatment, BrdU pulse-labeling experiments were performed. Figure 5C shows that BrdU incorporation was preferentially decreased in mid and late-S-phase cells at the end of the camptothecin treatment (1 mM camptothecin for 3 h) both in HCT116 wt and in p21À/À cells (panels e and d). At 6 h after camptothecin removal, BrdU incorporation was further decreased in the late-S-phase both in HCT116 wt and p21À/À cells (panels g and f). By contrast, UCN-01-treated HCT116 wt cells (panel h) had almost normal BrdU incorporation, consistent with S-phase checkpoint abrogation by UCN-01 (Shao et al., 1997a) . Together, these cell cycle analyses indicate that p21À/À cells have no further S-phase checkpoint deficiency when compared with the HCT116 wt cells.
UCN-
gH2AX accumulation in HCT116 p21À/À cells is independent from ongoing DNA replication To investigate the influence of DNA replication on the generation of gH2AX in p21À/À cells following camptothecin removal, we tested the effect of aphidicolin, a known inhibitor of replication DNA polymerases (Huberman, 1981) , which blocks replication-mediated DNA double-strand breakage in camptothecin-treated cells (Strumberg et al., 2000; Furuta et al., 2003) . We added aphidicolin after removal of camptothecin. Aphidicolin by itself did not induce gH2AX in p21À/À cells ( Figure 6 , panel e) and did not suppress the increase of gH2AX after removal of camptothecin in HCT116 p21 À/À cells ( Figure 6 : compare panels d and c). Thus, accumulation of gH2AX in p21À/À cells following topoisomerase I-mediated DNA damage does not require ongoing DNA synthesis.
UCN-01 further enhances camptothecin-induced gH2AX
in p21À/À cells Finally, we tested whether UCN-01 could enhance camptothecin-induced gH2AX in a p21-independent manner. We treated p21À/À cells with or without UCN-01 after camptothecin removal and measured the intensity of gH2AX. As shown in Figure 7 , UCN-01 further enhanced gH2AX intensity in p21À/À cells indicating that UCN-01 can activate gH2AX independently of p21
CDKN1A
.
Discussion
The present study demonstrates that replicationmediated DNA DSBs induced by camptothecin and detected by gH2AX formation increase markedly in cells with a deficient p53/p21 CDKN1A pathway, as such cells reach late-S-and G2 phase. TUNEL staining confirmed that gH2AX is induced by DSBs unrelated to apoptosis. 
UCN-01, p21, and cH2AX induced by camptothecin T Furuta et al
Thus, we propose that replication DSBs are generated by topoisomerase I cleavage complexes in response to unrepaired replication fork damage (see Figure 8 ). Camptothecin induces replication-mediated DSBs when replication forks collide with the topoisomerase I cleavage complexes trapped by camptothecin on the leading strand for DNA synthesis. We previously referred to these DSBs as 'replication run-off' (Figure 8 : inset) (Strumberg et al., 2000) . These replicationmediated DSBs are the primary lethal cytotoxic lesions of camptothecins (Pommier et al., 2003) . As topoisomerase I is expressed both in cancer and in normal tissues, the selective toxicity of camptothecins for cancer cells is likely due to cancer-related defects in DNA repair and checkpoints pathways (Pommier et al., 2003; Pommier et al., 2006) . The present experiments demonstrate that in the absence of p53/p21 CDKN1A or in cells treated with UCN-01, DSBs accumulate at the end of S-and in G2 phase (Figure 3) , which explains the previous observation that defects in the p53/p21 CDKN1A pathway increase the sensitivity of cancer cells to camptothecins (Gupta et al., 1997; Han et al., 2002) .
UCN-01 is an anticancer drug in clinical trials (Senderowicz, 2002; Dancey and Sausville, 2003) . In model systems, UCN-01 is especially effective in combination with camptothecin (Shao et al., 1997a) and other S-phase-specific chemotherapeutic agents ( Figure 2A . Before camptothecin treatment (No CPT), BrdU incorporation was observed mainly in the S phase both in HCT116 p21À/ À (a) and HCT116 wt cells (b). UCN-01 alone (0.1 mM for 6 h) did not affect the BrdU incorporation pattern (compare b and c). At the end of the camptothecin treatment (R0), BrdU incorporation was similarly decreased in the late S phase cells for both the HCT116 wt (e) and HCT116 p21À/À cells (d). At 6 h after camptothecin removal (R6), BrdU incorporation was mainly observed in the early S-phase cells both in the case of the HCT116 wt (g) and p21À/À cells (f). By contrast, UCN-01 restored BrdU incorporation throughout S phase (h). These results demonstrate S-phase checkpoint activation in HCT116 p21À/À cells as well as in HCT116 wt cells, and S-phase checkpoint abrogation by UCN-01 in HCT116 wt cells. Abbreviations: CL ¼ control untreated cells; R0 ¼ at the end of the treatment with 1 mM of camptothecin for 3 h; R6 ¼ 6 h after removal of camptothecin.
UCN-01, p21, and cH2AX induced by camptothecin T Furuta et al S-phase checkpoint abrogation by UCN-01 (Shao et al., 1997b; Shao et al., 2004) could lead to an accumulation of replication-mediated DSBs as persistent replication forks would continue to collide with unrepaired topoisomerase I cleavage complexes. The present study shows that UCN-01 also inhibits p21 CDKN1A upregulation (Yu et al., 2002) . Thus, UCN-01 could induce the formation of DSBs in response to camptothecin by two mechanisms: inhibition of p21 upregulation and S-phase checkpoint abrogation (Shao et al., 1997a) (Figure 8 ). Both checkpoint abrogation and p21 CDKN1A downregulation probably contribute to the enhanced gH2AX formation by UCN-01. Indeed, p21À/À cells accumulate gH2AX without S-phase checkpoint defect (compared to wt cells) (see Figure 5) (Wyllie et al., 1996; Guo et al., 1999) , and UCN-01 further enhances gH2AX formation in p21À/À cells (see Figure 7) . Chk1 is one of the key targets of UCN-01 (Busby et al., 2000; Graves et al., 2000) . Chk1 is required to stabilize damaged replication forks and to prevent their collapse, that leads to gH2AX formation (Syljuasen et al., 2005) . Hence, it is plausible that the p21 CDKN1A -independent enhancing effect of UCN-01 on gH2AX formation is primarily related to Chk1 inhibition (Syljuasen et al., 2005) .
p21
CDKN1A is known to block endoreduplication in the late phases of the cell cycle (Taylor and Stark, 2001; Vaziri et al., 2003) . p21 CDKN1A can regulate DNA replication/repair by inhibiting processive DNA synthesis in a PCNA-dependent manner, as it does for the repair of UV damage (Stivala et al., 2001) . p21 CDKN1A targets active cdk's to genomic regions that need to be repaired (Waga and Stillman, 1998) . However, our experiments showing that aphidicolin added after removal of camptothecin fails to block DSB formation in p21
CDKN1A -deficient cells (see Figure 6 ) argue against an endoreduplicative mechanism as the origin of the DSBs in p21
CDKN1A -deficient cells. Instead, our observations imply a direct role for p21 CDKN1A in the repair/ stabilization of replication-mediated DSBs induced by topoisomerase I cleavage complexes. Replicationmediated DSBs induced by camptothecin are repaired by homologous recombination (HR) both in yeast (reviewed in Pommier et al., 2003 Pommier et al., 2006 and at http:// www.discover.nci.nih.gov/pommier/pommier.htm) and mammalian cells (Godthelp et al., 2002; Hinz et al., 2003) . In addition, nonhomologous end joining (NHEJ) contributes to the repair of camptothecin-induced DSB (Shao et al., 1999; Hinz et al., 2003) . A variety of proteins are involved in HR for the repair of DSBs, Figure 6 Aphidicolin does not inhibit the increase of gH2AX focus formation after removal of camptothecin in HCT116 p21À/À cells. (A) Treatment schedule: p21À/À cells were treated with 1 mM camptothecin (CPT) for 3 h. Immediately after removal of camptothecin (R0), cells were incubated with aphidicolin (1 mM) (R6, þ APH) or without aphidicolin (R6). Samples were analysed for gH2AX before treatment (CL), at the end of the camptothecin treatment (R0), and 6 h after removal of camptothecin (R6). (B) Aphidicolin (1 mM) alone for 6 h (e) did not induce gH2AX foci. The formation of gH2AX foci in camptothecin-treated cells (b) increased at 6 h after drug removal (c), and was not inhibited by aphidicolin (d). Abbreviations: CL ¼ control untreated cells; R0 ¼ at the end of the treatment with 1 mM of camptothecin for 3 h; R6 ¼ 6 h after removal of camptothecin. Hoeijmakers, 2001; Larminat et al., 2004) . After DNA damage, Rad51 is overexpressed and forms foci associated with p21 CDKN1A expression (Raderschall et al., 2002) . Downregulation of p21 CDKN1A inhibits rad51 focus formation (Raderschall et al., 2002) . Therefore, in cells deficient for p21
CDKN1A or in cells whose p21 CDKN1A expression is downregulated by UCN-01, rad51-dependent DSB-repair pathway may be impaired. We hypothesize that defects in the rad51-DSB-repair (HR) pathway might be related to the accumulation of DSBs in p53À/À or p21À/À cells and in cells treated with UCN-01 after removal of camptothecin.
Defects in the p53/p21 CDKN1A pathways might contribute to DNA mutations and carcinogenesis because topoisomerase I cleavage complexes can be induced independently of camptothecin by endogenous and frequent DNA lesions (such as abasic sites and oxidative base damage) (Pourquier and Pommier, 2001 ) and by carcinogenic DNA adducts Antony et al., 2004 ) (reviewed in Pommier et al., 2003 , 2006 and at http://www.discover.nci.nih.gov/pommier/ pommier.htm). Thus, our observations lead us to speculate that replication DSBs induced by stabilized topoisomerase I cleavage complexes need to be repaired in the late-S-and G2/M phases in a p21 CDKN1A -and Chk1-dependent manner (Figure 8 ). Deficiency of p21 CDKN1A or Chk1 might lead to a failure to stabilize and repair damaged replication forks that might break ('collapse') as cells reach the end of their cell cycle.
Material and methods

Cell culture
Human colon carcinoma and HCT116 wt, p53À/À and p21À/ À cells were kindly provided by Dr Bert Vogelstein, Johns Hopkins University, Baltimore, USA. They were grown at 371C in the presence of 5% CO 2 in DMEM medium supplemented with 10% fetal bovine serum (FBS) (Gibco-BRL, Grand Island, NY), 100 U/ml penicillin and 100 mg/ml streptomycin.
Drugs, chemicals and antibodies
Camptothecin and UCN-01 were provided by the Drug Synthesis Chemistry Branch, Division of Cancer Treatment, National Cancer Institute (NCI). Aphidicolin was purchased from SIGMA (Sigma Chemical Co., St Louis, MO, USA). Aliquots were stored frozen at 10 mM in dimethylsulfoxide (DMSO) (Sigma Chemical Co., Louis, MO, USA) and diluted further in medium immediately prior to each experiment. AntigH2AX mouse monoclonal antibody were purchased from Upstate (Upstate, Altham, MA, USA). Anti-p21 waf1/cip1 antibody was purchased from Santa Cruiz (Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA). The secondary antimouse IgG (immunoglobulin G) antibodies conjugated with Alexa 488 were purchased from Molecular Probes (Molecular Probes, Inc., Eugene, OR, USA). The secondary anti-mouse IgG antibody conjugated with horseradish peroxidase was purchased from Amersham Biosciences UK Ltd. (Little Chalfont, Buckinghamshire, UK).
Laser scanning confocal microscopy Cells were grown on chamber slides. After treatment with indicated doses of camptothecin with or without UCN-01, or aphidicolin at 371C, the cell preparations were fixed in 2% paraformaldehyde in phosphate-buffered saline (PBS) for 5 min, washed in PBS, permeabilized in 100% methanol at À201C for 20 min, washed, blocked with PBS containing 1% of bovine serum albumin (BSA) and 5% of goat serum (Jackson Immunolabs, West Grove, PA, USA) for 1 h, incubated with anti-gH2AX primary antibody at 800-fold dilution for 2 h, washed, incubated with an Alexa 488-conjugated goat anti-mouse IgG secondary antibody at 200-fold dilution for 1 h and washed in PBS. Slides were treated with 10 U/ml of ribonuclease (Sigma Chemical Co., Louis, MO, USA) and stained with propidium iodide (PI). The slides were mounted with mounting medium (Vectashield, Vector Laboratories, Inc., Burlingame, CA, USA), and viewed with a PCM2000 laser scanning confocal microscope (Nikon Co., Tokyo, Japan) using a Â 40 or Â 100 objectives. The projection was saved as a BMP file. The intensity of gH2AX was measured by the calculation of the ratio of the green signal intensity (gH2AX) to red signal intensity (PI: Nucleus). Data are expressed as the mean7s.e. values of three independent experiments. (Strumberg et al., 2000) . Aphidicolin (APH) inhibits repDSBs and gH2AX formation by arresting replication (Furuta et al., 2003) . UCN-01 inhibits Chk1 and Chk2 kinases (Busby et al., 2000; Graves et al., 2000; Yu et al., 2002) . Chk2 and Chk1 stabilize p53, which induces p21 CDKN1A . Both Chk1 and p21 CDKN1A stabilizes stalled replication forks (reviewed in Pommier et al., 2003 Pommier et al., , 2006 and at http://www.discover.nci.nih.gov/pommier/pommier.htm).
, activation; , inhibition UCN-01, p21, and cH2AX induced by camptothecin T Furuta et al LSC Slides of cells stained with Propidium iodide, the anti-gH2AX primary antibody and the Alexa 488-conjugated secondary antibody prepared by the protocol as described above were subjected to analysis by LSC (LSC s , CompuCyte, Cambridge, MA, USA). The DNA content and intensity of FITC signal from each cell were determined.
Western blot analysis for gH2AX Cells were grown to 50-80% confluence when treated with different agents. Cells were scraped and pelleted by centrifugation at 01C at 1000 rpm for 15 min. The pellets were washed twice in PBS, homogenized in 0.2 N of H 2 SO 4 , and centrifuged at 13 000 rpm. Histones were pelleted from the supernatant by adding the 1/4 volume of 100% (w/v) trichloroacetic acid (TCA). The pellets were suspended in 100% ethanol overnight and centrifuged again at 13 000 rpm. The pellets were dissolved in Ultra pure water and evaluated for protein concentration (Bio-Rad, Hercules, CA, USA). Aliquots corresponding to 10 mg of protein were boiled in SDS sample buffer (TrisGlycine SDS Sample Buffer (2 Â ), Invitrogen Corporation, Carlsbad, CA, USA) and electrophoresed on 4-20% Tris Glycine precast gels (Novex, San Diego, CA, USA) and transferred to a polyvynilidene difluoride (PVDF) membrane (Immobilon-P, Millipore, Bedford, MA, USA). The membrane was blocked with 5% nonfat milk in TBST (10 mM TrisHCl pH 7.4, 200 mM NaCl, 0.1% Tween 20) for 1 h prior to incubation with 50 ng/ml anti-gH2AX primary antibody for 2 h. The blots were washed in TBST, then incubated with horseradish peroxidase-conjugated anti-mouse antibody (1/ 1000 dilution) and visualized by chemiluminescence using the Supersignal kit (SuperSignal s West Pico Chemiluminescent Substrate, PIERCE, Rockford, IL, USA). All the presented data were confirmed in independent experiments.
Western blotting analysis for p21
CDKN1A
Cells were grown to 50-80% confluence when treated with the different agents. Cells were scraped and washed twice with icecold PBS, then incubated on ice for 30 min in lysis buffer (0.3% NP-40, 25 mM NaF, 150 mM NaCl, 2 mM EGTA, 1 mM EDTA, 0.2% Triton X-100, 50 mM Tris-HCl pH 7.4, 1 mM PMSF, 5 mg/ml aprotinin, 100 mM leupeptin and 2 mM AEBSF). Cell debris was removed by centrifugation at 13 000 rpm for 15 min at 41C. Supernatant was evaluated for protein concentration and either used immediately or stored at À701C.
Cell lysates containing 40 mg of total protein were boiled in SDS sample buffer, electrophoresed in Tris-Glycine precast gels (Novex, San Diego, CA, USA) and transferred to Immobilont-P membranes. The membrane was blocked with 5% nonfat milk in TBST for 1 h prior to incubation with antip21 waf1/cip1 primary antibody (1/1000 dilution) for 2 h. After washing with TBST for 5 min three times, the membranes were incubated with horseradish peroxidase-conjugated anti-mouse antibody (1/1000 dilution) and visualized by chemiluminescence using the Supersignal kit (PIERCE, Rockford, IL, USA). The presented result was confirmed in independent experiments.
Flow cytometry
For cell cycle analyses, control and treated cells were fixed in 70% ethanol, washed, treated with RNase A, stained with PI, and subjected to flow microfluorimetry on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA).
For BrdU incorporation studies, cells were treated with 1 mM camptothecin or DMSO (control) followed by UCN-01 or medium alone in accordance with the treatment schedule. All further steps were performed in the dark. BrdU was added to a final concentration of 0.2 mM, 90 min before harvest. At the completion of the incubations, cells were trypsinized, centrifuged at 1000 rpm for 5 min, washed in ice-cold PBS, and fixed in 70% (v/v) ethanol at À201C for 6 h. After rehydration with PBS, samples were incubated with anti-BrdU antibody for 1 h, washed in PBS, treated with fluorescein-conjugated secondary antibody for 30 min, washed in PBS, incubated for 20 min at 371C in PBS supplemented with 50 mg/ml PI and 0.1 mg/ml RNase A, and subjected to flow cytometry. BrdU incorporation and cell cycle distribution were analysed using Becton Dickinson Cell Quest software (Mountain View, CA, USA).
For the Annexin V staining, PBS-washed cells were resuspended in 500 ml of Annexin V binding buffer, stained with Annexin V FITC, and then, subjected to analyses by FACScan cytometry in accordance with the manufacture protocol (Annexin V-FITC Apoptosis Detection Kit. Medical & Biological Laboratories Co., Ltd, Nagoya, Japan).
TUNEL assays
Cells seeded on the chamber slides were treated with 1 mM camptothecin or diluent followed by UCN-01 or medium alone in accordance with the treatment schedule. DNA breaks were analysed by TUNEL assay using the In situ Cell Death Detection Kit (Roche Molecular Biochemicals, Mannheim, Germany) in accordance with the manufacturer's protocol. Slides were scanned by the fluorescent microscopy (Olympus, Tokyo, Japan).
Abbreviations
BSA, bovine serum albumin; FBS, fetal bovine serum; DMSO, dimethylsulfoxide; DSB, DNA-double strand break; IR, ionizing radiation; LSC, laser scanning cytometry; p53À/À, deficient for p53; p21À/À, deficient for p21 CDKN1A ; PBS, phosphate-buffered saline; PVDF, polyvynilidene difluoride; TBS, Tris-buffered saline; TBS-T, Tris-buffered saline with Tween 20; TCA, trichloroacetic acid; TUNEL, terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling; UCN-01, 7-hydroxystaurosporine; wt, wild type.
